Shedding of Stock Holdings
Sleep Cycle, the leading sleep tracker application used in over 150 countries, continues to make waves in the sleep research industry. Collaborating with renowned universities and research facilities worldwide, the company based in Gothenburg, Sweden, has analyzed over 400 million nights of sleep data since its launch in 2009.
Sleep Cycle's mission to improve global health by empowering people to sleep better has resonated with millions, helping them understand their sleeping habits and improve their sleep. The company's success has not gone unnoticed, as evidenced by its listing on Nasdaq Stockholm under the ticker SLEEP.
Recent reports, however, have raised questions about potential changes in the company's shareholding structure. On September 8, 603,023 shares of Sleep Cycle AB were divested, representing 3.0% of shares and votes. Among the sellers was Carl Johan Hederoth, the company's CEO. Despite these developments, it is essential to clarify that there is no confirmation or public reporting of recent CEO share divestment or institutional investor buying/selling activities specific to Sleep Cycle AB as of mid-to-late 2025.
Investors seeking up-to-date and detailed information on executive or institutional share transactions are advised to refer to direct filings with stock exchanges, company press releases, or financial disclosures from Sleep Cycle AB or relevant regulatory bodies.
For more information about Sleep Cycle, you can visit the company's website or contact Carl Johan Hederoth directly. Per Andersson, the CFO and Head of Investor Relations, can be reached at per.andersson@our website or 46 70 939 5327. Malin Abrahamsson, the Head of PR, can be contacted at press@our website or 46 73 972 6424.
Following the transaction, Carl Johan Hederoth holds 79,572 shares, with 404,749 subscription warrants in Sleep Cycle. Despite the share sale, Carl Johan Hederoth's long-term confidence in Sleep Cycle remains unchanged.
[1] Vivos Therapeutics Financial Results (Source: Yahoo Finance) [2] Idorsia Half-Year Results 2025 (Source: Idorsia Pharmaceuticals Ltd.) [3] EQT AB Share Buyback (Source: Nasdaq European Market Activity) [4] Asahi Kasei Financial Summary (Source: Asahi Kasei Corporation) [5] Novo Nordisk Q2 2025 Results (Source: Novo Nordisk A/S)
[1] Despite selling a portion of his shares in Sleep Cycle, Carl Johan Hederoth, the company's CEO, maintains his long-term confidence in the sleep tracker app's potential for growth and in the broader finance and investing landscape.
[2] As Sleep Cycle AB continues to expand its business globally, investors seeking opportunities in the health tech sector may find interest in Finance and Investing related news and reports, such as those from companies like Vivos Therapeutics, Idorsia Pharmaceuticals Ltd., EQT AB, Asahi Kasei Corporation, and Novo Nordisk A/S.
